Search details
1.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36493792
2.
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Breast Cancer Res Treat
; 186(2): 417-428, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33392835
3.
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
J Clin Oncol
; 42(9): 987-993, 2024 Mar 20.
Article
in English
| MEDLINE | ID: mdl-38194616
4.
A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer.
Oncology
; 82(1): 25-9, 2012.
Article
in English
| MEDLINE | ID: mdl-22269428
5.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
J Clin Oncol
; 38(34): 3987-3998, 2020 12 01.
Article
in English
| MEDLINE | ID: mdl-32954927
6.
Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States.
J Thorac Dis
; 11(11): 4474-4483, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31903235
7.
Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer.
Curr Med Res Opin
; 35(10): 1761-1767, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31125266
8.
Cot/Tpl2 and PKCzeta cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain.
Cell Signal
; 19(8): 1652-61, 2007 Aug.
Article
in English
| MEDLINE | ID: mdl-17398070
9.
Differential regulation of p65 and c-Rel NF-kappaB transactivating activity by Cot, protein kinase C zeta and NIK protein kinases in CD3/CD28 activated T cells.
Cell Signal
; 19(3): 528-37, 2007 Mar.
Article
in English
| MEDLINE | ID: mdl-17070014
10.
The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC.
J Thorac Oncol
; 13(8): 1183-1188, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29733908
11.
Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial.
Int J Radiat Oncol Biol Phys
; 101(4): 927-934, 2018 07 15.
Article
in English
| MEDLINE | ID: mdl-29976505
12.
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Curr Med Res Opin
; 34(5): 865-871, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29424248
13.
Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.
Curr Med Res Opin
; 33(5): 931-936, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28276253
14.
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.
Curr Med Res Opin
; 33(5): 937-941, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28277871
15.
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
Clin Lung Cancer
; 18(5): 489-496, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28479368
16.
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol
; 34(9): 953-62, 2016 Mar 20.
Article
in English
| MEDLINE | ID: mdl-26811519
17.
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 15(6): 418-25, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25104617
18.
Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
J Thorac Oncol
; 9(7): 991-997, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24926544
19.
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Clin Transl Oncol
; 14(6): 430-6, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22634531
20.
Protein kinase Czeta phosphorylates nuclear factor of activated T cells and regulates its transactivating activity.
J Biol Chem
; 277(30): 27073-80, 2002 Jul 26.
Article
in English
| MEDLINE | ID: mdl-12021260
Results
1 -
20
de 20
1
Next >
>>